Results 71 to 80 of about 3,395 (155)

Economic aspects of the cardiology program expansion of additional drugs provision by effective lipidlowering drugs for hypercholesterolemia control

Качественная клиническая практика
The federal program of preferential drug provision in cardiology shows its effectiveness. However, hypercholesterolemia (HCH) remains a significant problem in patients in whom high-dose statin therapy does not provide the target level of low-density ...
O. V. Obuhova, A. S. Bogomazova, A. N. Meshkov, M. V. Ezhov   +3 more
doaj   +1 more source

Introducing the 'Drucebo' Effect in Statin Therapy: A systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. [PDF]

, 2018
Background: The ‘placebo effect’ and ‘nocebo effect’ are phenomena whereby beneficial (placebo) or adverse (nocebo) effects result from the expectation that an inert substance will relieve or cause a particular symptom.
Banach, Banach, Banach, Banach, Collins, Finegold, Ganga, Gupta, Haehling, Hall, Heller, Higgins, Hrobjartsson, Joy, Kashani, Kennedy, LaRosa, Manchikanti, Mancini, Moher, Moriarty, National Institute for Health and Care Excellence, Nissen, Nissen, Pasternak, Patel, Pravastatin Multicenter Study Group II, Riaz, Rojas-Mirquez, Rosenson, Rosenson, Serban, Sever, Taylor, Thompson, Thompson, Tobert, Toth, Zhang   +38 more
core   +2 more sources

Acute Myocardial Infarction: Molecular Pathogenesis, Diagnosis, and Clinical Management

MedComm, Volume 6, Issue 10, October 2025.
Key pathogenic mechanisms in AMI. Oxidative stress and mitochondrial dysfunction induce ROS accumulation, while DAMPs‐PRRs interaction triggers inflammatory cascades. Programmed cell death pathways and epigenetic regulation collectively constitute the core components of AMI pathogenesis.
Mengmeng Zhu, Yiwen Li, Qian Xu, Wenting Wang, Yanfei Liu, Yue Liu   +5 more
wiley   +1 more source

Mechanism‐Based Modeling Approaches to Quantify the Effect of Immunogenicity on the Pharmacokinetics of Therapeutic Proteins in Drug Development

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 9, Page 1431-1441, September 2025.
ABSTRACT Therapeutic protein administration in both preclinical and clinical studies can result in the formation of anti‐drug antibodies against the therapeutic protein. Anti‐drug antibody formation may alter the pharmacokinetics of the therapeutic protein, reduce its plasma concentrations, increase exposure variability, and may lead to a loss of ...
Paridhi Gupta, Josiah T. Ryman, Vibha Jawa, Bernd Meibohm   +3 more
wiley   +1 more source

Miscellanea. Folyóirat-referátumok. Könyvismertetés [PDF]

, 2016
Addiktológia. Új HIV-esetek Magyarországon az injekciós droghasználók körében: Téves riasztás vagy korai figyelmeztetés? (New cases of HIV among people who inject drugs in Hungary: False alarm or early warning?) Rácz, J., Gyarmathy, V. A.,
Apor, Péter, Fischer, Tamás, Forrai, Judit, Gáspárdy, Géza, Kalapos, Miklós Péter, Schneider, Imre   +5 more
core   +1 more source

Effect of Statins and PCSK9 Inhibition on Metabolic Dysfunction–Associated Steatotic Liver Disease

Journal of Digestive Diseases, Volume 26, Issue 9-10, Page 392-397, September-October 2025.
Statins reduce low‐density lipoprotein‐cholesterol (LDL‐C) production and reduce cardiovascular risk and hepatic steatosis in metabolic dysfunction‐associated steatotic liver disease (MASLD), but they have no significant effect on steatohepatitis and/or fibrosis.
Eleni Theocharidou, Thomas Gossios
wiley   +1 more source

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis

Frontiers in Pharmacology
BackgroundAlirocumab and evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors that significantly reduce the relative risk of cardiovascular events.
Leyu Xu, Leyu Xu, Ming Lei, Ming Lei, Liren Li, Liren Li, Yilei Li, Yilei Li, Chunping Gu, Chunping Gu, Ping Zheng, Ping Zheng   +11 more
doaj   +1 more source

A novel COL4A1 frameshift mutation in familial kidney disease: the importance of the C-terminal NC1 domain of type IV collagen [PDF]

, 2016
BACKGROUND: Hereditary microscopic haematuria often segregates with mutations of COL4A3, COL4A4 or COL4A5 but in half of families a gene is not identified. We investigated a Cypriot family with autosomal dominant microscopic haematuria with renal failure
Connor, TM, Gale, DP, Khan, N, Lapsley, M, Lin, F, Maxwell, PH, Neild, GH, Oygar, DD, Oygar, PD   +8 more
core   +1 more source

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, Volume 27, Issue S8, Page 34-46, September 2025.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source

Chronic kidney disease and valvular heart disease: State of the art

Physiological Reports, Volume 13, Issue 18, September 2025.
Abstract Chronic kidney disease (CKD) and valvular heart disease (VHD) frequently coexist and are associated with a significant increase in morbidity and mortality. Their interplay is complex and multifactorial, involving shared pathophysiological mechanisms such as chronic inflammation, mineral and bone disorder, vascular and valvular calcification ...
S. Saltarocchi, M. D'Abramo, P. De Orchi, F. Spunticchia, M. Totaro, E. M. Cirio, F. Miraldi   +6 more
wiley   +1 more source